Comprehensive analysis of GVHD regulated cells by high dimensional cytometry and identification of prognostic factors
Project/Area Number |
15K09508
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Hematology
|
Research Institution | Sapporo Medical University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
佐藤 勉 札幌医科大学, 医学部, 講師 (40404602)
小船 雅義 札幌医科大学, 医学部, 准教授 (90336389)
|
Project Period (FY) |
2015-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2015: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Keywords | GVHD / Treg / 高次元サイトメトリー / 高次元サイトメトリー法 / BH3 profiling |
Outline of Final Research Achievements |
In chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation, individual differences in severity are large, so identification of GVHD predictive factors and development of a novel control method are desired. In this study, we comprehensively analyzed cGVHD regulatory cells after transplantation by using high-dimensional cytometry in combination with BH3 profiling and clarified the usefulness of IL-2 therapy.
|
Report
(4 results)
Research Products
(10 results)
-
-
-
-
-
-
-
-
[Journal Article] Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial.2015
Author(s)
Hirayama Y, Ishitani K, Sato Y, Iyama S, Takada K, Murase K, Kuroda H, Nagamachi Y, Konuma Y, Fujimi A, Sagawa T, Ono K, Horiguchi H, Terui T, Koike K, Kusakabe T, Sato T, Takimoto R, Kobune M, Kato J
-
Journal Title
Int J Clin Oncol
Volume: 20
Issue: 5
Pages: 866-871
DOI
Related Report
Peer Reviewed
-
[Journal Article] A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer.2015
Author(s)
Sato Y, Ohnuma H, Hirakawa M, Takahashi M, Osuga T, Okagawa Y, Murase K, Takada K, Kawano Y, Iyama S, Hayashi T, Sato T, Miyanishi K, Takimoto R, Kobune M, Okita K, Mizuguchi T, Furuhata T, Hirata K, Kato J
-
Journal Title
Cancer Chemother Pharmacol
Volume: 75
Issue: 3
Pages: 587-597
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] RNAi-mediated gene silencing of ST6GalNAc I suppresses the metastatic potential in gastric cancer cells2014
Author(s)
Tamura F, Sato Y, Hirakawa M, Yoshida M, Ono M, Osuga T, Okagawa Y, Uemura N, Arihara Y, Murase K, Kawano Y, Iyama S, Takada K, Hayashi T, Sato T, Miyanishi K, Kobune M, Takimoto R, Kato J.
-
Journal Title
Gastric Cancer
Volume: 23
Issue: 1
Pages: 85-97
DOI
NAID
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant